EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
Current therapy for rheumatoid arthritis (RA) should not only suppress inflammation, but should also prevent local and generalized bone mineral density (BMD) loss. The drug of choice to treat secondary osteoporosis (OP) is denosumab, a monoclonal antibody, which binds RANKL, inhibiting the inte...
Saved in:
| Main Authors: | P. S. Dydykina, Е. V. Petrova, I. S. Dydykina, A. V. Smirnov, S. V. Glukhova, L. I. Alekseeva, E. L. Nasonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2015-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2066 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01) -
Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
by: T. A. Raskina, et al.
Published: (2015-09-01) -
Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01) -
Vitrum Osteomag and calcium carbonate efficacy comparative assessment in patients with rheumatoid arthritis receiving glucocorticoids
by: I S Dydykina, et al.
Published: (2004-02-01) -
Determination of the accuracy of osteoporotic fractures risk assessment in patients with rheumatoid arthritis using the prognostic model, developed at V.A. Nasonova Research Institute of Rheumatology, and the FRAX algorithm
by: P. O. Kozhevnikova, et al.
Published: (2021-10-01)